Selecta's targeted Synthetic Vaccine Particle (tSVP™) product platform enables the rational design of vaccines that can efficiently and selectively induce or modify cellular and/or humoral immune responses for therapeutic and prophylactic indications. The tSVP enables expanded opportunities for vaccines using Selecta’s tSVP platform, and the company is pursuing opportunities across a range of clinical applications, including infectious, metabolic, CNS and inflammatory diseases.  We expect our first product candidate to enter the clinic in 2011.